tophaceous

In tophaceous gout (which is marked by frequent recurrence), uric acid crystal deposits - called tophi - show up in the different tissues near the joints.

Hyperuricemia is Gout: Learning about Its Causes and Complexities 2007

With allopurinol it has been possible to prevent and reduce in the tophaceous deposits and to prevent urate stone formation (74), (81), (87), (89,90).

Nobel Lecture The Purine Path To Chemotherapy 1988

"With the dramatic reduction in serum uric acid observed when RDEA594 and febuxostat are administered in combination, together these agents may be able to produce reductions in tophaceous gout previously achieved only with intravenous therapy."

unknown title 2009

"With the dramatic reduction in serum uric acid observed when RDEA594 and febuxostat are administered in combination, together these agents may be able to produce reductions in tophaceous gout previously achieved only with intravenous therapy."

unknown title 2009

"With the dramatic reduction in serum uric acid observed when RDEA594 and febuxostat are administered in combination, together these agents may be able to produce reductions in tophaceous gout previously achieved only with intravenous therapy."

unknown title 2009

"The substantial reduction in serum uric acid observed when RDEA594 and febuxostat are co-administered indicate that these two oral agents with complementary mechanisms may be able to accelerate improvement in tophaceous gout compared to single agent therapy," commented John S. S.ndy MD, PhD, associate professor of medicine and head of the S.ction of Allergy and Clinical Immunology in the Division of Pulmonary, Allergy and Critical Care Medicine at Duke University Medical Center and a member of Ardea's scientific advisory board.

unknown title 2009

"The substantial reduction in serum uric acid observed when RDEA594 and febuxostat are co-administered indicate that these two oral agents with complementary mechanisms may be able to accelerate improvement in tophaceous gout compared to single agent therapy," commented John S. S.ndy MD, PhD, associate professor of medicine and head of the S.ction of Allergy and Clinical Immunology in the Division of Pulmonary, Allergy and Critical Care Medicine at Duke University Medical Center and a member of Ardea's scientific advisory board.

unknown title 2009

"The substantial reduction in serum uric acid observed when RDEA594 and febuxostat are co-administered indicate that these two oral agents with complementary mechanisms may be able to accelerate improvement in tophaceous gout compared to single agent therapy," commented John S. S.ndy MD, PhD, associate professor of medicine and head of the S.ction of Allergy and Clinical Immunology in the Division of Pulmonary, Allergy and Critical Care Medicine at Duke University Medical Center and a member of Ardea's scientific advisory board.

unknown title 2009